Form 6-K — CureVac N.V.: withdraw CVnCoV from the approval process with the European Medicines Agency (2021)
Summary
A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission for the month of October, 2021, Commission File Number 001-39446. It states that on October 12, 2021 the company issued a press release announcing that it will withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency and will refocus on second-generation mRNA vaccine candidates with GlaxoSmithKline Biologicals SA. It adds that the existing Advanced Purchase Agreement with the European Commission will cease as a result. The information is incorporated by reference into a Form F-3 registration statement, File No. 333-259613.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Form 6-K — CureVac N.V.: withdraw CVnCoV from the approval process with the European Medicines Agency (2021).”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-cvac-6-k-filed2021-10-12-0001104659-21-125072-99fad3b8f9/
, SHA-256 6e0256bd5120e2a67364ab23514e8a1cb9512fdfcb17065d67ef0e3120875e13.Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2021 Commission File Number: 001-39446 CureVac N.V. ( Exact Name of Registrant as Specified in Its Charter ) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F | x | Form 40-F | ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes | ¨ | No | x Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes | ¨ | No | x On October 12, 2021, CureVac N.V. (the “Company”) issued a press release announcing that the Company will withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency, and instead, will refocus its COVID-19 vaccine efforts towards the acceleration of the development of second-generation mRNA vaccine candidates in collaboration with GlaxoSmithKline Biologicals SA. As a result of the withdrawal, the existing Advanced Purchase Agreement with the European Commission, which was predicated on employing CVnCoV to address the acute pandemic need, will cease. The information included in this Form 6-K (including Exhibit 99.1, but excluding the statements of CureVac N.V.’s Chief Executive Officer and GSK’s Head of Vaccines R&D contained in Exhibits 99.1 thereto) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CUREVAC N.V. By: | /s/ Franz-Werner Haas, LLD, LLM Chief Executive Officer Date: October 12, 2021 EXHIBIT INDEX EXHIBIT NO. | DESCRIPTION 99.1 | CureVac N.V. Press Release dated October 12, 2021.
File and source
- File
- SEC_CVAC_6-K_filed2021-10-12_0001104659-21-125072.htm
- Size
- 14,223 bytes
- SHA-256
- 6e0256bd5120e2a67364ab23514e8a1cb9512fdfcb17065d67ef0e3120875e13
- Original
- www.sec.gov